MedPath

Psilocybin

Generic Name
Psilocybin
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C12H17N2O4P
CAS Number
520-52-5
Unique Ingredient Identifier
2RV7212BP0
Background

Psilocybin has been investigated for the treatment of Anxiety and Stage IV Melanoma. In November, 2019, it was granted Breakthrough Therapy status by the FDA.

Associated Conditions
-
Associated Therapies
-

Our DNA Could Affect the Potency of Psychedelics in the Brain

A study reveals genetic variations in serotonin receptors affect psychedelic drug potency, suggesting genetics should influence clinical trials for their therapeutic use. Different gene forms of the 5-HT2A receptor showed varied responses to psychedelics, indicating genetics play a role in individual sensitivity to these drugs.
oncnursingnews.com
·

Oncology Nursing News: Advancements in Cancer Treatment and Patient Care Strategies

Recent advancements in cancer treatment include psilocybin-assisted psychotherapy for mental health, pembrolizumab with radiotherapy and surgery for sarcoma, dordaviprone for glioma, and avutometinib with defactinib for ovarian cancer. Discussions on patient care strategies, EGFR-targeted therapies, and new drug approvals like zongertinib and tislelizumab highlight progress in oncology.
nyulangone.org
·

Psychedelic Drug Therapy May Address Mental Health Concerns in People with Cancer

A NYU study found that a single psilocybin dose with psychotherapy significantly improves emotional and existential distress in cancer patients, with effects lasting nearly five years. The treatment showed sustained reductions in anxiety, depression, and improved quality of life, offering a promising approach for cancer-related psychological care.

Therapeutic use of classic psychedelics to treat cancer-related psychological distress

Cancer patients often suffer psychological distress, with early research (1960s-1970s) indicating serotoninergic psychedelics (e.g., psilocybin, LSD) may help. Recent studies (2011-2016) confirm psychedelic-assisted therapy significantly improves cancer-related psychiatric and existential distress.

Psychedelics for Patients With Cancer: A Comprehensive Review

Psychedelics show promise in reducing anxiety and depression in cancer patients, with significant reductions noted in several trials. Benefits may extend 6-12 months post-treatment, offering a new option beyond traditional antidepressants. However, studies are limited by small sizes and methodological issues, including increased blood pressure and heart rate.
© Copyright 2025. All Rights Reserved by MedPath